• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型新辅助免疫治疗方案在头颈部鳞状细胞癌中的安全性和生存获益。

Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.

机构信息

Department of Otolaryngology-Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan, USA.

出版信息

Head Neck. 2011 Dec;33(12):1666-74. doi: 10.1002/hed.21660. Epub 2011 Jan 31.

DOI:10.1002/hed.21660
PMID:21284052
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4062188/
Abstract

BACKGROUND

Cellular immune suppression is observed in head and neck squamous cell cancer (HNSCC) and contributes to poor prognosis. Restoration of immune homeostasis may require primary cell-derived cytokines at physiologic doses. An immunotherapy regimen containing a biologic, with multiple-active cytokine components, and administered with cytoxan, zinc, and indomethacin was developed to modulate cellular immunity.

METHODS

Study methods were designed to determine the safety and efficacy of a 21-day neoadjuvant immunotherapy regimen in a phase 2 trial that enrolled 27 therapy-naïve patients with stage II to IVa HNSCC. Methods included safety, clinical and radiologic tumor response, disease-free survival (DFS), overall survival (OS), and tumor lymphocytic infiltrate (LI) data collection.

RESULTS

Acute toxicity was minimal. Patients completed neoadjuvant treatment without surgical delay. By independent radiographic review, 83% had stable disease during treatment. OS was 92%, 73%, and 69% at 12, 24, and 36 months, respectively. Histologic analysis suggested correlation between survival and tumor LI.

CONCLUSION

Immunotherapy regimen was tolerated. Survival results are encouraging.

摘要

背景

头颈部鳞状细胞癌（HNSCC）存在细胞免疫抑制，这与预后不良有关。恢复免疫稳态可能需要生理剂量的原代细胞衍生细胞因子。本研究开发了一种免疫治疗方案，其中包含一种生物制剂，具有多种活性细胞因子成分，并与环磷酰胺、锌和吲哚美辛联合使用，以调节细胞免疫。

方法

该研究方法旨在确定 27 例未经治疗的 II 期至 IVa 期 HNSCC 患者接受 21 天新辅助免疫治疗方案的安全性和有效性。方法包括安全性、临床和影像学肿瘤反应、无病生存（DFS）、总生存（OS）和肿瘤淋巴细胞浸润（LI）数据收集。

结果

急性毒性极小。患者在无手术延迟的情况下完成了新辅助治疗。通过独立的影像学评估，83%的患者在治疗期间疾病稳定。12、24 和 36 个月的 OS 分别为 92%、73%和 69%。组织学分析表明，生存与肿瘤 LI 之间存在相关性。

结论

免疫治疗方案可耐受。生存结果令人鼓舞。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/4062188/784ea9fe1580/nihms588900f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/4062188/ea6e72a127c0/nihms588900f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/4062188/9a0c530aca4a/nihms588900f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/4062188/043c253b15e0/nihms588900f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/4062188/996301a96000/nihms588900f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/4062188/784ea9fe1580/nihms588900f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/4062188/ea6e72a127c0/nihms588900f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/4062188/9a0c530aca4a/nihms588900f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/4062188/043c253b15e0/nihms588900f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/4062188/996301a96000/nihms588900f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0829/4062188/784ea9fe1580/nihms588900f5.jpg

相似文献

1
Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.新型新辅助免疫治疗方案在头颈部鳞状细胞癌中的安全性和生存获益。
Head Neck. 2011 Dec;33(12):1666-74. doi: 10.1002/hed.21660. Epub 2011 Jan 31.
2
A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck.一项评估 IRX-2 方案治疗头颈部鳞状细胞癌患者的安全性的 I 期研究。
Am J Clin Oncol. 2011 Apr;34(2):173-8. doi: 10.1097/COC.0b013e3181dbb9d8.
3
Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial.头颈部鳞状细胞癌的联合免疫疗法：一项2期试验。
Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):345-51. doi: 10.1001/archotol.126.3.345.
4
Neoadjuvant immunotherapy of oral squamous cell carcinoma modulates intratumoral CD4/CD8 ratio and tumor microenvironment: a multicenter phase II clinical trial.口腔鳞状细胞癌的新辅助免疫治疗可调节肿瘤内CD4/CD8比值及肿瘤微环境：一项多中心II期临床试验
J Clin Oncol. 2005 May 20;23(15):3421-32. doi: 10.1200/JCO.2005.06.005.
5
Covalent linking of proteins and cytokines to suture: enhancing the immune response of head and neck cancer patients.蛋白质和细胞因子与缝线的共价连接：增强头颈癌患者的免疫反应
Laryngoscope. 2003 Nov;113(11):1870-84. doi: 10.1097/00005537-200311000-00004.
6
Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck.头颈部复发性或转移性鳞状细胞癌的维持免疫治疗
J Immunother. 2008 May;31(4):413-9. doi: 10.1097/CJI.0b013e31816d1d8e.
7
Immune changes in peripheral blood resulting from locally directed interleukin-2 therapy in squamous cell carcinoma of the head and neck.头颈部鳞状细胞癌局部定向白细胞介素-2治疗引起的外周血免疫变化。
Eur J Cancer B Oral Oncol. 1993 Jan;29B(1):29-34. doi: 10.1016/0964-1955(93)90007-2.
8
Interleukins and contrasuppression induce immune regression of head and neck cancer.白细胞介素和反抑制诱导头颈癌的免疫消退。
Arch Otolaryngol Head Neck Surg. 1994 Apr;120(4):395-403. doi: 10.1001/archotol.1994.01880280023004.
9
A natural cytokine mixture (IRX-2) and interference with immune suppression induce immune mobilization and regression of head and neck cancer.一种天然细胞因子混合物（IRX - 2）以及对免疫抑制的干预可诱导免疫动员和头颈癌消退。
Int J Immunopharmacol. 1997 Nov-Dec;19(11-12):619-27. doi: 10.1016/s0192-0561(97)00059-3.
10
Characterization of the immune response in patients with cancer of the oral cavity after neoadjuvant immunotherapy with the IRX-2 regimen.IRX-2 方案新辅助免疫治疗后口腔癌患者免疫反应的特征。
Oral Oncol. 2021 Dec;123:105587. doi: 10.1016/j.oraloncology.2021.105587. Epub 2021 Oct 27.

引用本文的文献

1
Ferroptosis and oral squamous cell carcinoma: connecting the dots to move forward.铁死亡与口腔鳞状细胞癌：梳理脉络，砥砺前行。
Front Oral Health. 2024 Sep 4;5:1461022. doi: 10.3389/froh.2024.1461022. eCollection 2024.
2
Head and Neck Squamous Cell Carcinoma Vaccine: Current Landscape and Perspectives.头颈部鳞状细胞癌疫苗：现状与展望
Curr Issues Mol Biol. 2023 Nov 16;45(11):9215-9233. doi: 10.3390/cimb45110577.
3
Oral squamous cell carcinomas: state of the field and emerging directions.口腔鳞状细胞癌：研究现状与新兴方向。

本文引用的文献

1
A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck.一项评估 IRX-2 方案治疗头颈部鳞状细胞癌患者的安全性的 I 期研究。
Am J Clin Oncol. 2011 Apr;34(2):173-8. doi: 10.1097/COC.0b013e3181dbb9d8.
2
Immunotherapy of head and neck cancer: current and future considerations.头颈部癌症的免疫治疗：当前和未来的考虑。
J Oncol. 2009;2009:346345. doi: 10.1155/2009/346345. Epub 2009 Aug 9.
3
IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death.新型免疫疗法IRX-2可保护人类T细胞免受肿瘤诱导的细胞死亡。
Int J Oral Sci. 2023 Sep 22;15(1):44. doi: 10.1038/s41368-023-00249-w.
4
Global research trends in immunotherapy for head and neck neoplasms: A scientometric study.头颈部肿瘤免疫治疗的全球研究趋势：一项科学计量学研究。
Heliyon. 2023 Apr 13;9(4):e15309. doi: 10.1016/j.heliyon.2023.e15309. eCollection 2023 Apr.
5
Therapeutic Vaccination in Head and Neck Squamous Cell Carcinoma-A Review.头颈部鳞状细胞癌的治疗性疫苗接种——综述
Vaccines (Basel). 2023 Mar 13;11(3):634. doi: 10.3390/vaccines11030634.
6
Implications and Emerging Therapeutic Avenues of Inflammatory Response in HPV+ Head and Neck Squamous Cell Carcinoma.人乳头瘤病毒阳性头颈部鳞状细胞癌炎症反应的影响及新兴治疗途径
Cancers (Basel). 2022 Nov 2;14(21):5406. doi: 10.3390/cancers14215406.
7
Defining the Role of Immunotherapy in the Curative Treatment of Locoregionally Advanced Head and Neck Cancer: Promises, Challenges, and Opportunities.定义免疫疗法在局部晚期头颈癌根治性治疗中的作用：前景、挑战与机遇
Front Oncol. 2021 Sep 21;11:738626. doi: 10.3389/fonc.2021.738626. eCollection 2021.
8
Preoperative Immunotherapy in the Multidisciplinary Management of Oral Cavity Cancer.口腔癌多学科管理中的术前免疫治疗
Front Oncol. 2021 Jul 1;11:682075. doi: 10.3389/fonc.2021.682075. eCollection 2021.
9
Neoadjuvant immunotherapy in resectable head and neck cancer: oral cavity carcinoma as a potential research model.可切除头颈癌的新辅助免疫治疗：口腔癌作为潜在的研究模型
Ther Adv Med Oncol. 2021 Feb 23;13:1758835920984061. doi: 10.1177/1758835920984061. eCollection 2021.
10
The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma.口咽鳞状细胞癌的肿瘤微环境与免疫治疗
Front Oncol. 2020 Dec 21;10:545385. doi: 10.3389/fonc.2020.545385. eCollection 2020.
Cell Death Differ. 2009 May;16(5):708-18. doi: 10.1038/cdd.2008.197. Epub 2009 Jan 30.
4
Head and neck cancer.头颈癌
Lancet. 2008 May 17;371(9625):1695-709. doi: 10.1016/S0140-6736(08)60728-X.
5
Immunotherapy for head and neck cancer.头颈部癌的免疫疗法。
J Biomed Sci. 2008 May;15(3):275-89. doi: 10.1007/s11373-008-9247-x. Epub 2008 Apr 5.
6
Head and neck cancer immunotherapy: clinical evaluation.头颈部癌免疫疗法：临床评估
Curr Oncol Rep. 2008 Mar;10(2):162-9. doi: 10.1007/s11912-008-0025-8.
7
Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer.术前使用非甾体抗炎药（NSAID）可增加结直肠癌中看似被激活的免疫细胞的肿瘤组织浸润。
Cancer Immun. 2008 Feb 29;8:5.
8
Cancer statistics, 2008.2008年癌症统计数据。
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.
9
Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer?调节性T细胞：它们在头颈癌患者的抗肿瘤免疫中发挥什么作用？
Head Neck. 2008 Feb;30(2):251-61. doi: 10.1002/hed.20739.
10
IRX-2, a novel in vivo immunotherapeutic, induces maturation and activation of human dendritic cells in vitro.IRX-2是一种新型的体内免疫疗法，可在体外诱导人树突状细胞成熟和激活。
J Immunother. 2007 Sep;30(6):624-33. doi: 10.1097/CJI.0b013e3180691593.